In addition, although the infusion of IL-2-activated NK-cell-enriched populations or intravenous IL-2 infusions combined with subcutaneous IL-2 augmented in vivo the NK-cell function, there was a lack of consistent clinical efficacy of autologous NK-cell-based therapy in patients with lymphoma and breast cancer when compared with cohorts of matched controls (56). The gene discussed is IL2; the disease is lymphoma.